These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 20556670)

  • 41. Risks of Hip and Nonvertebral Fractures in Patients With CKD G3a-G5D: A Systematic Review and Meta-analysis.
    Vilaca T; Salam S; Schini M; Harnan S; Sutton A; Poku E; Allen IE; Cummings SR; Eastell R
    Am J Kidney Dis; 2020 Oct; 76(4):521-532. PubMed ID: 32654892
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Effects of raloxifene on fracture risk in postmenopausal women: the Raloxifene Use for the Heart Trial.
    Ensrud KE; Stock JL; Barrett-Connor E; Grady D; Mosca L; Khaw KT; Zhao Q; Agnusdei D; Cauley JA
    J Bone Miner Res; 2008 Jan; 23(1):112-20. PubMed ID: 17892376
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Reassessment of fracture risk in women after 3 years of treatment with zoledronic acid: when is it reasonable to discontinue treatment?
    Cosman F; Cauley JA; Eastell R; Boonen S; Palermo L; Reid IR; Cummings SR; Black DM
    J Clin Endocrinol Metab; 2014 Dec; 99(12):4546-54. PubMed ID: 25215556
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Risk of fracture in women treated with monthly oral ibandronate or weekly bisphosphonates: the eValuation of IBandronate Efficacy (VIBE) database fracture study.
    Harris ST; Reginster JY; Harley C; Blumentals WA; Poston SA; Barr CE; Silverman SL
    Bone; 2009 May; 44(5):758-65. PubMed ID: 19168160
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Risk factors for vertebral and nonvertebral fracture over 10 years: a population-based study in women.
    Finigan J; Greenfield DM; Blumsohn A; Hannon RA; Peel NF; Jiang G; Eastell R
    J Bone Miner Res; 2008 Jan; 23(1):75-85. PubMed ID: 17784843
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Strategies for treatment to prevent fragility fractures in postmenopausal women.
    Geusens P
    Best Pract Res Clin Rheumatol; 2009 Dec; 23(6):727-40. PubMed ID: 19945685
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Prevalence and Cost of Subsequent Fractures Among U.S. Patients with an Incident Fracture.
    Weaver J; Sajjan S; Lewiecki EM; Harris ST; Marvos P
    J Manag Care Spec Pharm; 2017 Apr; 23(4):461-471. PubMed ID: 28345441
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The gender- and age-specific 10-year and lifetime absolute fracture risk in Tromsø, Norway.
    Ahmed LA; Schirmer H; Bjørnerem A; Emaus N; Jørgensen L; Størmer J; Joakimsen RM
    Eur J Epidemiol; 2009; 24(8):441-8. PubMed ID: 19484362
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Use of strontium as a treatment method for osteoporosis.
    Cortet B
    Curr Osteoporos Rep; 2011 Mar; 9(1):25-30. PubMed ID: 21120641
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Comparative effects of raloxifene and alendronate on fracture outcomes in postmenopausal women with low bone mass.
    Recker RR; Kendler D; Recknor CP; Rooney TW; Lewiecki EM; Utian WH; Cauley JA; Lorraine J; Qu Y; Kulkarni PM; Gaich CL; Wong M; Plouffe L; Stock JL
    Bone; 2007 Apr; 40(4):843-51. PubMed ID: 17182297
    [TBL] [Abstract][Full Text] [Related]  

  • 51. BMD and risk of hip and nonvertebral fractures in older men: a prospective study and comparison with older women.
    Cummings SR; Cawthon PM; Ensrud KE; Cauley JA; Fink HA; Orwoll ES; ;
    J Bone Miner Res; 2006 Oct; 21(10):1550-6. PubMed ID: 16995809
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Sustained nonvertebral fragility fracture risk reduction after discontinuation of teriparatide treatment.
    Prince R; Sipos A; Hossain A; Syversen U; Ish-Shalom S; Marcinowska E; Halse J; Lindsay R; Dalsky GP; Mitlak BH
    J Bone Miner Res; 2005 Sep; 20(9):1507-13. PubMed ID: 16059622
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Continuous broad protection against osteoporotic fractures with strontium ranelate.
    Ferrari S
    Rheumatology (Oxford); 2009 Oct; 48 Suppl 4():iv20-4. PubMed ID: 19783590
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Osteoporosis: from early fracture prevention to better bone health with strontium ranelate.
    Cortet B
    Rheumatology (Oxford); 2009 Oct; 48 Suppl 4():iv14-9. PubMed ID: 19783589
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Risedronate for treatment of osteoporosis].
    Hagino H
    Nihon Rinsho; 2009 May; 67(5):948-53. PubMed ID: 19432115
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Long-Term Drug Therapy and Drug Discontinuations and Holidays for Osteoporosis Fracture Prevention: A Systematic Review.
    Fink HA; MacDonald R; Forte ML; Rosebush CE; Ensrud KE; Schousboe JT; Nelson VA; Ullman K; Butler M; Olson CM; Taylor BC; Brasure M; Wilt TJ
    Ann Intern Med; 2019 Jul; 171(1):37-50. PubMed ID: 31009947
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Recognition of women at risk for fracture and intervention with fast-acting therapies.
    Derman R
    Int J Fertil Womens Med; 2006; 51(4):183-90. PubMed ID: 17184104
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Zoledronic acid and clinical fractures and mortality after hip fracture.
    Lyles KW; Colón-Emeric CS; Magaziner JS; Adachi JD; Pieper CF; Mautalen C; Hyldstrup L; Recknor C; Nordsletten L; Moore KA; Lavecchia C; Zhang J; Mesenbrink P; Hodgson PK; Abrams K; Orloff JJ; Horowitz Z; Eriksen EF; Boonen S;
    N Engl J Med; 2007 Nov; 357(18):1799-809. PubMed ID: 17878149
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Risk factors associated with incident clinical vertebral and nonvertebral fractures in postmenopausal women: the Canadian Multicentre Osteoporosis Study (CaMos).
    Papaioannou A; Joseph L; Ioannidis G; Berger C; Anastassiades T; Brown JP; Hanley DA; Hopman W; Josse RG; Kirkland S; Murray TM; Olszynski WP; Pickard L; Prior JC; Siminoski K; Adachi JD
    Osteoporos Int; 2005 May; 16(5):568-78. PubMed ID: 15517191
    [TBL] [Abstract][Full Text] [Related]  

  • 60. T-Score as an Indicator of Fracture Risk During Treatment With Romosozumab or Alendronate in the ARCH Trial.
    Cosman F; Lewiecki EM; Ebeling PR; Hesse E; Napoli N; Matsumoto T; Crittenden DB; Rojeski M; Yang W; Libanati C; Ferrari S
    J Bone Miner Res; 2020 Jul; 35(7):1333-1342. PubMed ID: 32445228
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.